The tariff classification of Elinzanetant (CAS No. 929046-33-3) in bulk form and LYNKUET® (E linzanetant) Capsules in dosage form, from Germany
No revocation or modification of this ruling appears in the Customs Bulletin issues read here (Nov 6, 2024 through Nov 18, 2026), where CBP publishes most such actions. That is not confirmation that the ruling is still in effect. Confirm its status with CBP before relying on it (ruling on CBP CROSS).
Key passages, quoted from the ruling
- The applicable subheading for the Elinzanetant in bulk form will be 2934.99.3000, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Nucleic acids and their salts, whether or not chemically defined; other heterocyclic compounds: Other: Other: Aromatic or modified aromatic: Other: Drugs.” The general rate of duty will be 6.5 percent ad valorem.
Ruling text
In your letter dated January 5, 2026, you requested a tariff classification ruling. Elinzanetant is a neurokinin 1 (NK1) and neurokinin 3 (NK3) receptor antagonist that acts on the central nervous system (CNS). It is indicated for the treatment of moderate to severe vasomotor symptoms (VMS; also known as hot flashes) associated with menopause or endocrine therapy (ET) for breast cancer. Lynkuet, imported in 60 mg capsule form, is a neurokinin 1 (NK1) and neurokinin 3 (NK3) receptor antagonist.
It is indicated as an alternative to hormonal replacement therapy for women who cannot use hormone-based treatments for the treatment of moderate to severe vasomotor symptoms, commonly known as hot flashes, associated with menopause.
The applicable subheading for the Elinzanetant in bulk form will be 2934.99.3000, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Nucleic acids and their salts, whether or not chemically defined; other heterocyclic compounds: Other: Other: Aromatic or modified aromatic: Other: Drugs.” The general rate of duty will be 6.5 percent ad valorem. Currently, Elinzanetant is not listed in the Pharmaceutical Appendix to the Tariff Schedule.
The applicable subheading for the Lynkuet capsules in dosage form will be 3004.90.9240, HTSUS, which provides for “Medicaments … consisting of mixed or unmixed products for therapeutic or prophylactic uses, put up in measured doses … or in forms or packings for retail sale: Other: Other: Other: Medicaments primarily affecting the central nervous system: Other.” The general rate of duty will be free. The duties cited above are current as of this ruling’s issuance.
Duty rates are provided for your convenience and are subject to change. The text of the most recent HTSUS and the accompanying duty rates are provided at https://hts.usitc.gov/. This merchandise may be subject to the Federal Food, Drug, and Cosmetic Act and/or The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which are administered by the U.S. Food and Drug Administration (FDA).
Information on the Federal Food, Drug, and Cosmetic Act, as well as The Bioterrorism Act, can be obtained by calling the FDA at 1-888-463-6332, or by visiting their website at www.fda.gov. This ruling does not address the applicability of any additional duties, taxes, fees, exactions and/or other charges, which may apply to the goods discussed herein. This includes, but is not limited to, tariffs and other duties as provided for in Subchapter III to Chapter 99, HTSUS.
Thus, for example, in addition to the classification stated above, the merchandise covered by this ruling may also need to be reported with either the Chapter 99 provision under which an additional tariff applies or one of the Chapter 99 provisions covering exceptions to such tariffs.
The text above is an excerpt. The official ruling, with its letterhead, signature and any attachments, is on CBP CROSS (N357497).